Influenza — The Respiratory Protection Effectiveness Clinical Trial
Citation(s)
Anzueto A, Niederman MS Diagnosis and treatment of rhinovirus respiratory infections. Chest. 2003 May;123(5):1664-72. Review.
Askarian M, Mirzaei K, Honarvar B, Etminan M, Araujo MW Knowledge, attitude and practice towards droplet and airborne isolation precautions among dental health care professionals in Shiraz, Iran. J Public Health Dent. 2005 Winter;65(1):43-7.
Askarian M, Mirzaei K, Mundy LM, McLaws ML Assessment of knowledge, attitudes, and practices regarding isolation precautions among Iranian healthcare workers. Infect Control Hosp Epidemiol. 2005 Jan;26(1):105-8.
Bettinardi O, Argentero P, Giorgi I [Assessment of occupational stress among workers in rehabilitation medicine]. G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):693-5. Italian.
Bridges CB, Kuehnert MJ, Hall CB Transmission of influenza: implications for control in health care settings. Clin Infect Dis. 2003 Oct 15;37(8):1094-101. Epub 2003 Sep 19.
Burke JP Infection control - a problem for patient safety. N Engl J Med. 2003 Feb 13;348(7):651-6.
Christini AB, Shutt KA, Byers KE Influenza vaccination rates and motivators among healthcare worker groups. Infect Control Hosp Epidemiol. 2007 Feb;28(2):171-7. Epub 2007 Jan 17.
Daley P, Castriciano S, Chernesky M, Smieja M Comparison of flocked and rayon swabs for collection of respiratory epithelial cells from uninfected volunteers and symptomatic patients. J Clin Microbiol. 2006 Jun;44(6):2265-7.
Daugherty EL, Perl TM, Rubinson L, Bilderback A, Rand CS Survey study of the knowledge, attitudes, and expected behaviors of critical care clinicians regarding an influenza pandemic. Infect Control Hosp Epidemiol. 2009 Dec;30(12):1143-9. doi: 10.1086/648085.
Elder AG, O'Donnell B, McCruden EA, Symington IS, Carman WF Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993-4 epidemic: results of serum testing and questionnaire. BMJ. 1996 Nov 16;313(7067):1241-2.
Evans ME, Hall KL, Berry SE Influenza control in acute care hospitals. Am J Infect Control. 1997 Aug;25(4):357-62.
Fendrick AM, Monto AS, Nightengale B, Sarnes M The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003 Feb 24;163(4):487-94.
Fisher E, Rengasamy S, Viscusi D, Vo E, Shaffer R Development of a test system to apply virus-containing particles to filtering facepiece respirators for the evaluation of decontamination procedures. Appl Environ Microbiol. 2009 Mar;75(6):1500-7. doi: 10.1128/AEM.01653-08. Epub 2009 Jan 9.
Fisher LD, Dixon DO, Herson J, et al (1990) Intention to treat in clinical trials. In: Peace KE (Ed.), Statistical issues in drug research and development (pp. 331-50). New York, NY: Marcel Dekker.
Gammon J, Morgan-Samuel H, Gould D A review of the evidence for suboptimal compliance of healthcare practitioners to standard/universal infection control precautions. J Clin Nurs. 2008 Jan;17(2):157-67. Epub 2007 Mar 1. Review.
Ginocchio CC Detection of respiratory viruses using non-molecular based methods. J Clin Virol. 2007 Nov;40 Suppl 1:S11-4. doi: 10.1016/S1386-6532(07)70004-5. Review.
Grinshpun SA, Haruta H, Eninger RM, Reponen T, McKay RT, Lee SA Performance of an N95 filtering facepiece particulate respirator and a surgical mask during human breathing: two pathways for particle penetration. J Occup Environ Hyg. 2009 Oct;6(10):593-603. doi: 10.1080/15459620903120086.
ICH Expert Working Group (1998) ICH Harmonised Tripartite Guideline, Statistical Principles for Clinical Trials E9, Current Step 4 version dated 5 February 1998. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf (last accessed 04 June 2017).
Jarvis WR Infection control and changing health-care delivery systems. Emerg Infect Dis. 2001 Mar-Apr;7(2):170-3. Review.
Johnson DF, Druce JD, Birch C, Grayson ML A quantitative assessment of the efficacy of surgical and N95 masks to filter influenza virus in patients with acute influenza infection. Clin Infect Dis. 2009 Jul 15;49(2):275-7. doi: 10.1086/600041.
Radonovich LJ Jr, Hodgson MJ, Cohen HJ Do respirators protect health-care workers from airborne infectious diseases? Respir Care. 2008 Dec;53(12):1660-4.
Radonovich LJ Jr, Perl TM, Davey V, Cohen H Preventing the soldiers of health care from becoming victims on the pandemic battlefield: respirators or surgical masks as the armor of choice. Disaster Med Public Health Prep. 2009 Dec;3 Suppl 2:S203-10. doi: 10.1097/DMP.0b013e3181be830c.
Rengasamy S, Eimer BC, Shaffer RE Comparison of nanoparticle filtration performance of NIOSH-approved and CE-marked particulate filtering facepiece respirators. Ann Occup Hyg. 2009 Mar;53(2):117-28. doi: 10.1093/annhyg/men086.
Schafer JL Multiple imputation: a primer. Stat Methods Med Res. 1999 Mar;8(1):3-15. Review.
U S. Department of Health and Human Services: Food and Drug Administration (2005). Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials. Rockville, MD: Food and Drug Administration.
Whitehead J Sample size calculations for ordered categorical data. Stat Med. 1993 Dec 30;12(24):2257-71. Erratum in: Stat Med 1994 Apr 30;13(8):871.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.